Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.54 |
| ▸ | GRM6 | O15303 | 2/20 | 0.54 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25323809 | 1.00 | GRM8 (0.54) | GRM8GRM6GRM7GRM4GRIN2D | |
| SCHEMBL9003756 | 0.89 | OTC (0.58) | GRM8GRM6GRM7GRM4GRIN2D | |
| SCHEMBL9003744 | 0.89 | OTC (0.58) | GRM8GRM6GRM7GRM4GRIN2D | |
| SCHEMBL27872833 | 0.80 | ALOX15 (0.76) | GRM8GRM6GRM7GRM4GRIN2D | |
| SCHEMBL22164119 | 0.80 | ALOX15 (0.76) | GRM8GRM6GRM7GRM4GRIN2D | |
| SCHEMBL8467545 | 0.79 | OTC (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1431004 | 0.79 | OTC (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL195547 | 0.79 | OTC (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Glutamic Acid SCHEMBL49767 | 0.77 | GRM8 (0.82) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL1065173 | 0.77 | GRM8 (0.82) | GRM8GRM6GRM7GRM4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140271926-A1 | METHODS OF USE OF GLUTAMINE SYNTHETASE INHIBITORS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2014-09-18 | — | — | US | claimed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | claimed |
| CN-116457468-A | Production of high-yielding recombinant chinese hamster ovary cell lines for therapeutic protein production | 赛诺菲 | 2023-07-18 | — | — | CN | disclosed |
| US-10947598-B2 | Methods for determining the metabolic status of lymphomas | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-03-16 | — | — | US | disclosed |
| EP-3356551-B1 | METHODS FOR DETERMINING THE METABOLIC STATUS OF B-LYMPHOMAS | INST NAT SANTE RECH MED (FR) | 2020-09-02 | — | — | EP | disclosed |
| US-20180282816-A1 | METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS | Université Côte d'Azur (FR) | 2018-10-04 | — | — | US | disclosed |
| EP-3356551-A1 | METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20140271926-A1 | METHODS OF USE OF GLUTAMINE SYNTHETASE INHIBITORS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2014-09-18 | — | — | US | disclosed |
| WO-2012095514-A1 | RECOMBINANT PROTEIN PRODUCTION SYSTEM | VIVALIS (FR) | 2012-07-19 | — | — | WO | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| EP-1965778-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NewThera (FR) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | GRM8 256/4885GRM6 67/4885GRM7 146/4885 |
| US-10947598-B2 | Methods for determining the metabolic status of lymphomas | GAPDH, GCDH, IDH2 | GRM8 2699/4885GRM6 2265/4885GRM7 2256/4885 |
| US-20180282816-A1 | METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS | GAPDH, IDH2, GCDH | GRM8 3171/4885GRM6 2510/4885GRM7 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.